BORONATED METALLOPORPHYRINS - A NOVEL-APPROACH TO THE DIAGNOSIS AND TREATMENT OF CANCER USING CONTRAST-ENHANCED MR IMAGING AND NEUTRON-CAPTURE THERAPY

被引：23

作者：

HUANG, LR ^{[1
]}

STRAUBINGER, RM ^{[1
]}

KAHL, SB ^{[1
]}

KOO, MS ^{[1
]}

ALLETTO, JJ ^{[1
]}

MAZURCHUK, R ^{[1
]}

CHAU, RI ^{[1
]}

THAMER, SL ^{[1
]}

FIEL, RJ ^{[1
]}

机构：

[1] ROSWELL PK CANC INST,DEPT BIOPHYS,ELM & CARLTON ST,BUFFALO,NY 14263

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1993年 / 3卷 / 02期

关键词：

BORON; CONTRAST ENHANCEMENT; CONTRAST MEDIA; MANGANESE; NEOPLASMS; MR; THERAPY; PORPHYRIN; UTILIZATION;

D O I：

10.1002/jmri.1880030210

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Porphyrins are a unique class of metal chelating agents that have shown specific affinity for neoplasms. The water-soluble free-base derivative, tetrakiscarborane carboxylate ester of 2,4- (alpha,beta-dihydroxyethyl) deuteroporphyrin IX (BOPP), an agent designed for neutron capture therapy, has previously demonstrated selective localization and retention in a C6 murine glioma. In the present work, the authors demonstrate that the manganese chelate of BOPP also selectively localizes in a rat 9L gliosarcoma and preferentially enhances the tumor-normal brain contrast of T1-weighted images for at least 92 hours. The data indicate a maximal enhancement of contrast between tumor and normal brain at 24 hours after injection, compared with 5 minutes for manganese (III) tetraphenylporphine sulfonate (TPPS4). The results also indicate that Mn-BOPP may have a slower uptake in the 9L glioma than Mn-TPPS4 but a longer retention in the tumor. Mn-BOPP is unique in that it represents, to the authors' knowledge, the first example of a single agent that can enhance contrast between tumor and normal tissue and be potentially effective as an agent for boron neutron capture therapy.

引用

页码：351 / 356

页数：6

共 30 条

[1]

Weinmann HJ, Laniado M, Mutzel W, Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers, Physiol Chem Phys Med NMR, 16, pp. 167-172, (1984)

[2]

Felix R, Schorner W, Laniado M, Et al., Brain tumors: MR imaging with gadolinium‐DTPA, Radiology, 156, pp. 681-688, (1985)

[3]

Winkelman J, The distribution of tetraphenylporphine‐sulfonate in the tumor‐bearing rat, Cancer Res, 22, pp. 589-595, (1962)

[4]

Winkelman J, Slater G, Grossman J, The concentration in tumor and other tissues of parenterally administered tritium‐ and <sup>14</sup>C‐labeled tetraphenylporphinesulfonate, Cancer Res, 27, pp. 2060-2064, (1967)

[5]

Lipson R, Baldes E, Olson A, The use of a derivative of hematoporphyrin in tumor detection, J Natl Cancer Inst, 26, pp. 1-8, (1961)

[6]

Barker D, Henderson R, Storey E, The in vivo localization ofporphyrins, Br J Exp Pathol, 51, pp. 628-638, (1970)

[7]

Musser DA, Wagner JM, Datta-Gupta N, Distribution of tetraphenylporphinesulfonate and tetracarboxylphenylporphine in tumor‐bearing mice, J Natl Cancer Inst, 61, pp. 1397-1403, (1978)

[8]

Chen CW, Cohen JS, Myers CE, Sohn M, Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging, FEBS Lett, 168, pp. 70-74, (1984)

[9]

Ogan MD, Revel D, Brasch RC, Metalloporphyrin contrast enhancement of tumors in magnetic resonance imaging: a study of human carcinoma, lymphoma, and fibrosarcoma in mice, Invest Radiol, 22, pp. 822-828, (1987)

[10]

Fiel RJ, Button T., Gilani S, Et al., Proton relaxation enhancement by Mn(III)TPPS<sub>4</sub> in a model tumor system, Magn Reson Imaging, 5, pp. 149-156, (1987)

← 1 2 3 →